PRNewsWire
18 Mar 2026, 20:05 UTC · 33w ago
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Impact · against what's priced in
Sera Prognostics significantly reduces immediate bankruptcy risk by securing a cash runway through 2028 and provides critical clinical validation via the PRIME study. However, the lack of meaningful revenue growth ($81k in 2025) indicates that commercial adoption remains speculative.
- SERA+0.40
No priced-in read yet
- In context
The company provides a substantial liquidity cushion of $95.8 million to fund operations through 2028 and has published the PRIME study, which serves as a necessary catalyst for payer coverage. These positives are tempered by stagnant revenue of $81,000 and a net loss of $31.9 million.
Read from the article alone
